Search research articles
Contact Us
Filters
Showing results (11-20 of 40) with videos related to
Page
of 4
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging
|
November 30, 2019
Clinical outcome of standardized <sup>177</sup>Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Sazan Rasul, Marcus Hacker, Elisabeth Kretschmer-Chott, et al.
Prostate Cancer and Prostatic Diseases
|
September 30, 2020
Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [<sup>68</sup>Ga]Ga-PSMA ligand PET/CT(MRI)
Bernhard Grubmüller, Victoria Jahrreiss, Nicolai Huebner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 19, 2023
Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer
Valentin Al Jalali, Gabriel Wasinger, Sazan Rasul, et al.
Scandinavian Journal of Urology
|
January 25, 2020
Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer
David D'Andrea, Francesco Soria, Sonja Zehetmayer, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer
Bernhard Grubmüller, Nicolai A Huebner, Sazan Rasul, et al.
European Urology Open Science
|
May 31, 2022
Feasibility and Optimal Time Point of [<sup>68</sup>Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
Nicolai Huebner, Sazan Rasul, Pascal Baltzer, et al.
Clinical Epigenetics
|
February 26, 2025
Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study
Kilian Kluge, Vincent Lotz, Holger Einspieler, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
February 25, 2020
The prognostic impact of tumour NSD2 expression in advanced prostate cancer
Judith Stangl-Kremser, Ursula Lemberger, Melanie R Hassler, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 31, 2020
Prediction of response and survival after standardized treatment with 7400 MBq <sup>177</sup>Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
Sazan Rasul, Markus Hartenbach, Tim Wollenweber, et al.
Urologic Oncology
|
January 21, 2024
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET
Nicolai A Huebner, Gabriel Wasinger, Pawel Rajwa, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 40) with videos related to
Sort By:
Page
of 4
European Journal of Nuclear Medicine and Molecular Imaging
|
November 30, 2019
Clinical outcome of standardized <sup>177</sup>Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks
Sazan Rasul, Marcus Hacker, Elisabeth Kretschmer-Chott, et al.
Prostate Cancer and Prostatic Diseases
|
September 30, 2020
Differential impact of radiation therapy after radical prostatectomy on recurrence patterns: an assessment using [<sup>68</sup>Ga]Ga-PSMA ligand PET/CT(MRI)
Bernhard Grubmüller, Victoria Jahrreiss, Nicolai Huebner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 19, 2023
Consecutive Prostate-Specific Membrane Antigen (PSMA) and Antigen Receptor (AR) PET Imaging Shows Positive Correlation with AR and PSMA Protein Expression in Primary Hormone-Naïve Prostate Cancer
Valentin Al Jalali, Gabriel Wasinger, Sazan Rasul, et al.
Scandinavian Journal of Urology
|
January 25, 2020
Comparative effectiveness of radical cystectomy and radiotherapy without chemotherapy in frail patients with bladder cancer
David D'Andrea, Francesco Soria, Sonja Zehetmayer, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Dual-Tracer PET-MRI-Derived Imaging Biomarkers for Prediction of Clinically Significant Prostate Cancer
Bernhard Grubmüller, Nicolai A Huebner, Sazan Rasul, et al.
European Urology Open Science
|
May 31, 2022
Feasibility and Optimal Time Point of [<sup>68</sup>Ga]Gallium-labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography Imaging in Patients Undergoing Cytoreductive Surgery After Systemic Therapy for Primary Oligometastatic Prostate Cancer: Implications for Patient Selection and Extent of Surgery
Nicolai Huebner, Sazan Rasul, Pascal Baltzer, et al.
Clinical Epigenetics
|
February 26, 2025
Imaging and outcome correlates of ctDNA methylation markers in prostate cancer: a comparative, cross-sectional [⁶⁸Ga]Ga-PSMA-11 PET/CT study
Kilian Kluge, Vincent Lotz, Holger Einspieler, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals
|
February 25, 2020
The prognostic impact of tumour NSD2 expression in advanced prostate cancer
Judith Stangl-Kremser, Ursula Lemberger, Melanie R Hassler, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
October 31, 2020
Prediction of response and survival after standardized treatment with 7400 MBq <sup>177</sup>Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer
Sazan Rasul, Markus Hartenbach, Tim Wollenweber, et al.
Urologic Oncology
|
January 21, 2024
Clinical parameters for the prediction of occult lymph node metastasis in patients with negative PSMA-PET
Nicolai A Huebner, Gabriel Wasinger, Pawel Rajwa, et al.
Page
of 4